Varenicline increases smoking abstinence at 6 months to a year compared with placebo or bupropion; nausea is the most commonly reported adverse effect

Evidence-Based Medicine

Volumn 16, Issue 4, 2011, Pages 113-114

  Sofuoglu, Mehmet ^a   Duffey, Dianne ^a   Mooney, Marc E ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO; VARENICLINE;

AGITATION; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG EFFICACY; DRUG MARKETING; HUMAN; MENTAL DISEASE; META ANALYSIS (TOPIC); MOOD CHANGE; NAUSEA; NOTE; PSYCHOSOCIAL CARE; SMOKING CESSATION; SUICIDAL IDEATION;

EID: 79960639940     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1200     Document Type: Note

References (2)

1. Sofuoglu M, Herman AI, Mooney M, et al. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl) 2009;207:153-62.
2. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004;61:1107-15. (Pubitemid 39463411)